Preclinical News and Research

RSS

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Using new one-of-a-kind "mouse models" that promise to have a significant impact on future Parkinson's disease research, Mount Sinai School of Medicine researchers are among the first to discover how mutations in a gene called LRRK2 may cause inherited (or "familial") Parkinson's disease, the most common form of the disease. The study, published in The Journal of Neuroscience, is the first in vivo evidence that LRRK2 regulates dopamine transmission and controls motor performance, and that the mutation of LRRK2 eliminates the normal function of LRRK2, leading to Parkinson's disease.

1 Apr 2010

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.

1 Apr 2010

LAB Research reports 9% decrease in revenues for 2009

LAB Research Inc., a global Canadian-based non-clinical contract research organization, today announced its fourth quarter and 2009 year-end financial results.

1 Apr 2010

Major breakthrough may help develop low toxicity drugs for sleeping sickness

Scientists from the Drug Discovery Unit at the University of Dundee - working together with partners at the University of York and the Structural Genomics Consortium in Toronto - have made a major breakthrough in identifying new treatments for a fatal disease which infects tens of thousands of Africans each year.

1 Apr 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, reports its financial results for the fourth quarter and full year ended December 31, 2009, and on its progress for the year.

31 Mar 2010

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Pfizer Canada is pleased to announce the recipients of its third Neuropathic Pain Research Awards Competition, which aims to fund and support Canadian innovation within independent neuropathic pain research in the areas of basic biomedical, clinical and health sciences.

31 Mar 2010

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Today AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept").

31 Mar 2010

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

The Fairbanks Institute for Healthy Communities, the Indianapolis not-for-profit organization working to improve community health, and BioServe, a global provider of biomaterial and genetic research services, today announced that they will co-market INbank™, a next generation biorepository that was recently launched by The Fairbanks Institute.

31 Mar 2010

Cell Therapeutics agrees to sell $20M of Series 4 Preferred Stock and warrants to institutional investors

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell $20 million of shares of its Series 4 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors.

31 Mar 2010

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

ACCESS PHARMACEUTICALS, INC. signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin™-based oral insulin and other Cobalamin-based products.

31 Mar 2010

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV. The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection.

30 Mar 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

StockPreacher.com releases investment report on MDRNA

StockPreacher.com announces an investment report featuring drug developer MDRNA Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

30 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.

30 Mar 2010

Preclinical News and Research

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

LAB Research reports 9% decrease in revenues for 2009

Major breakthrough may help develop low toxicity drugs for sleeping sickness

RXi Pharmaceuticals reports net loss of 28% for 2009

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

Cell Therapeutics agrees to sell $20M of Series 4 Preferred Stock and warrants to institutional investors

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

StockPreacher.com releases investment report on MDRNA

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

Preclinical study of DAS181 for treatment and prevention of ILI published

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics